Search

Your search keyword '"loncastuximab tesirine"' showing total 142 results
Start Over "loncastuximab tesirine" Publisher right vision media
142 results on '"loncastuximab tesirine"'

1. EU Contract Notice: Universitatsklinikum Munster Issues contract notice|solicitation for 'IIT study CLEAR 'Combining Loncastuximab Tesirine and Epcoritamab in Relapsed|Refractory Diffuse Large B-cell Lymphoma (DLBCL)'

Subjects
Lymphomas, Contract agreement, Business, international
Abstract

Luxembourg: Universitatsklinikum Munster has issued contract notice/solicitation for 'IIT study CLEAR 'Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)' Reference no: 639713-2024 Posted on: 22/10/2024 Notice [...]

Published
2024

2. ZYNLONTA (Loncastuximab Tesirine) for Diffuse Large B-cell lymphoma (DLBCL) - Drug Insight and Market Forecasts, 2019-2032

Subjects
Lymphomas -- Forecasts and trends -- Reports, Market trend/market analysis, General interest, News, opinion and commentary, Zynlonta (Medication) -- Reports
Abstract

DUBLIN: RESEARCH AND MARKETS has issued the following news release: The 'ZYNLONTA Drug Insight and Market Forecast - 2032' drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides [...]

Published
2024

3. ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA(r) (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

Subjects
ADC Therapeutics S.A. -- Product development, Clinical trials, General interest, News, opinion and commentary
Abstract

LAUSANNE, Switzerland: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today announced a voluntary pause in the enrollment of new patients in the Phase [...]

Published
2023

4. ADC Therapeutics and Sobi Announced European Commission Approval of ZYNLONTA(r) (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Subjects
ADC Therapeutics S.A., Lymphomas -- Care and treatment, Drug approval, General interest, News, opinion and commentary, European Union. European Commission
Abstract

LAUSANNE: ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi(r)) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA(r) (loncastuximab tesirine) [...]

Published
2022

5. Zynlonta(r) (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Subjects
ADC Therapeutics S.A., Lymphomas -- Care and treatment, Drug approval, Pharmaceutical industry, General interest, News, opinion and commentary, European Union. European Commission
Abstract

STOCKHOLM: Swedish Orphan Biovitrum AB has issued the following press release: Sobi(r) and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the [...]

Published
2022

6. ADC Therapeutics and Sobi Announce ZYNLONTA(r) (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Subjects
ADC Therapeutics S.A. -- Licensing agreements -- Research agreements, Non-Hodgkin's lymphomas -- Care and treatment, Drug approval, Pharmaceutical industry -- Research agreements -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary, European Union. European Commission
Abstract

LAUSANNE: ADC THERAPEUTICS SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi(r)) today announced the Committee for Medicinal Products for Human [...]

Published
2022

7. ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA(r) (loncastuximab tesirine-lpyl) in Europe and Select International Territories

Subjects
ADC Therapeutics S.A. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following press release: ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB [...]

Published
2022

8. ADC Therapeutics Announces FDA Approval of ZYNLONTA (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Subjects
United States. Food and Drug Administration, ADC Therapeutics S.A., Biological products, Non-Hodgkin's lymphomas -- Drug therapy, Drug approval, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) [...]

Published
2021

9. Loncastuximab Tesirine: (Lonca, formerly ADCT-402): An Antibody Drug Conjugate Composed of a Humanized Monoclonal Antibody Directed Against Human CD19 - Emerging Insight and Market Forecast 2021-2030

Subjects
Biopharmaceutics -- Reports, Lymphomas -- Reports, Monoclonal antibodies -- Reports, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Loncastuximab Tesirine - Emerging Insight and Market Forecast - 2030' report has been added to ResearchAndMarkets.com's offering. This report [...]

Published
2021

10. ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network(r) Clinical Practice Guidelines in Oncology for B-cell Lymphomas

Subjects
ADC Therapeutics S.A., Biological products, Lymphomas -- Care and treatment, Cancer -- Care and treatment, Pharmaceutical industry, General interest, News, opinion and commentary, National Comprehensive Cancer Network
Abstract

LAUSANNE: ADC THERAPEUTICS SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat [...]

Published
2021

11. ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting

Subjects
ADC Therapeutics S.A. -- Conferences, meetings and seminars, Ibrutinib -- Conferences, meetings and seminars, Brentuximab vedotin -- Conferences, meetings and seminars, Professional associations -- Conferences, meetings and seminars, Biopharmaceuticals -- Conferences, meetings and seminars, Pembrolizumab -- Conferences, meetings and seminars, Antibodies -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Analog to digital converters -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted [...]

Published
2020

12. ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1|2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Subjects
ADC Therapeutics S.A. -- Product development, Biological products -- Product development, Diseases -- Relapse, Non-Hodgkin's lymphomas, Clinical trials, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following press release: ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) [...]

Published
2020

13. ADC Therapeutics reports data from Phase 2 clinical trial of ZYNLONTA

Subjects
ADC Therapeutics S.A. -- Product development, Lymphomas, Clinical trials, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, University of Miami, Zynlonta (Medication) -- Product development
Abstract

LAUSANNE: ADC Therapeutics SA announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal [...]

Published
2024

14. ADC Therapeutics notifies updates on LOTIS-7 clinical trial evaluating ZYNLONTA(r)

Subjects
Non-Hodgkin's lymphomas, Clinical trials, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA(r) (loncastuximab tesirine-lpyl) in combination with bispecific antibodies [...]

Published
2024

15. ADC Therapeutics gibt erste Ergebnisse der von Prufarzten initiierten klinischen Phase-II-Studie zur Bewertung von ZYNLONTA(r) in Kombination mit Rituximab b

Subjects
ADC Therapeutics S.A. -- Product development, Lymphomas, Clinical trials, Bendamustine, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase II clinical trial evaluating ZYNLONTA(r) (Loncastuximab-tesirine-Lpyl) in [...]

Published
2023

16. ADC Therapeutics to present at the 65th ASH Annual Meeting

Subjects
ADC Therapeutics S.A., Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA announced abstracts on ZYNLONTA (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in [...]

Published
2023

17. Why ADC Therapeutics shares are faling today?

Subjects
General interest, News, opinion and commentary
Abstract

LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma. The move comes after a recent review of summary [...]

Published
2023

18. ADC Therapeutics to present at the European Hematology Association 2023 Hybrid Congress

Subjects
ADC Therapeutics S.A., Societies, Associations, institutions, etc., Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been [...]

Published
2023

19. ADC Therapeutics to present LOTIS-2 Trial results at EHA2023 Hybrid Congress

Subjects
ADC Therapeutics S.A. -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been [...]

Published
2023

20. ADC Therapeutics Announce Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

Subjects
ADC Therapeutics S.A. -- Conferences, meetings and seminars, Biological products -- Conferences, meetings and seminars, Stem cells -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

LAUSANNE, Switzerland: ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA(r) (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented [...]

Published
2022

21. ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

Subjects
ADC Therapeutics S.A. -- Conferences, meetings and seminars, Lymphomas -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA(r) (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for [...]

Published
2022

22. ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA(r)

Subjects
ADC Therapeutics S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, international
Abstract

LAUSANNE: ADC Therapeutics SA announced the first patient has been dosed in LOTIS-9, a Phase 2 clinical trial evaluating ZYNLONTA(r) (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in unfit and [...]

Published
2022

23. ZYNLONTA Now Approved for the Treatment of Adult Patients with Relapsed|Refractory Large B Cell Lymphoma After Two or More Lines of Systemic Therapy

Subjects
United States. National Cancer Institute, Non-Hodgkin's lymphomas -- Care and treatment, Epidemiology, General interest, News, opinion and commentary
Abstract

LOUISVILLE, Ky.: Onco360(r), the nation's largest independent Oncology Pharmacy, has been selected by ADC Therapeutics to be the exclusive specialty pharmacy partner for ZYNLONTA (loncastuximab tesirine-lpyl), a new intravenous therapy [...]

Published
2021

24. ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA(r) in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Subjects
United States. Food and Drug Administration, ADC Therapeutics S.A. -- Product development, Biological products -- Product development, Lymphomas, Clinical trials, General interest, News, opinion and commentary, Zynlonta (Medication) -- Product development
Abstract

LAUSANNE, Switzerland: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), [...]

Published
2024

25. ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA(r) in Combination with Rituximab to Treat Relapsed|Refractory Follicular Lymphoma

Subjects
ADC Therapeutics S.A. -- Product development, Biological products -- Product development -- Evaluation, Diseases -- Relapse, Lymphomas, Bendamustine, General interest, News, opinion and commentary, Zynlonta (Medication) -- Evaluation
Abstract

LAUSANNE, Switzerland: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), [...]

Published
2024

26. Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Subjects
Nektar Therapeutics, Incyte Corp., Non-Hodgkin lymphomas, Clinical trials, Business research, Emapalumab, Nivolumab, Acalabrutinib, Pharmaceutical industry, Cemiplimab, Business -- Research, Non-Hodgkin's lymphomas
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various [...]

Published
2024

28. ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Subjects
ADC Therapeutics S.A. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Zynlonta (Medication)
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today [...]

Published
2024

29. ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Subjects
ADC Therapeutics S.A. -- Conferences, meetings and seminars, Biological products -- Conferences, meetings and seminars, Lymphomas -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Zynlonta (Medication)
Abstract

LAUSANNE, Switzerland: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), [...]

Published
2024

30. ADC Therapeutics Unveils Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Subjects
ADC Therapeutics S.A. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Societies -- Conferences, meetings and seminars -- Research, Biological products -- Conferences, meetings and seminars -- Research, Cancer -- Conferences, meetings and seminars -- Research, Associations, institutions, etc. -- Conferences, meetings and seminars -- Research, Pharmaceutical industry -- Conferences, meetings and seminars -- Research, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA announces abstracts on its novel antibody-drug conjugates have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held [...]

Published
2024

31. ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA(r) in Combination with Rituximab in Patients with Relapsed|Refractory Follicular Lymphoma (FL)

Subjects
ADC Therapeutics S.A. -- Company sales and earnings -- Product development, Diseases -- Relapse, Clinical trials, Bendamustine, Pharmaceutical industry -- Product development -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary
Abstract

LAUSANNE, Switzerland: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA(r) (loncastuximab [...]

Published
2023

32. The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight

Subjects
Takeda Pharmaceutical Company Ltd. -- Forecasts and trends, Bristol-Myers Squibb Co. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Regeneron Pharmaceuticals Inc. -- Forecasts and trends, AstraZeneca PLC -- Forecasts and trends, Business -- Research, Antineoplastic agents -- Forecasts and trends, Non-Hodgkin's lymphomas -- Forecasts and trends, B cells -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Antimitotic agents -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: B-cell lymphoma is a diverse group of blood cancers that originate from abnormal B lymphocytes, a type of [...]

Published
2023

33. Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seqtm for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

Subjects
Trade and professional associations -- Conferences, meetings and seminars, Non-Hodgkin's lymphomas -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

AURORA: Foresight Diagnostics has issued the following news release: Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seqtm [...]

Published
2023

34. ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Subjects
ADC Therapeutics S.A. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) reported financial results for the third quarter 2023 and provided business updates. 'During the third [...]

Published
2023

35. ADC market revenue to reach $29.6b

Subjects
ADC Therapeutics S.A. -- Reports, Pfizer Inc. -- Reports, ImmunoGen Inc. -- Reports, Insight Partners -- Reports, Antineoplastic agents -- Reports, Biological products -- Reports, Cancer -- Care and treatment, Venture capital companies -- Reports, Monoclonal antibodies -- Reports, Pharmaceutical industry -- Reports, Antimitotic agents -- Reports, General interest, News, opinion and commentary
Abstract

Pune: Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a [...]

Published
2023

36. Global Antibody Drug Conjugate (ADC) Market Trends and Forecasts Report 2023-2035: HER2 ADC to Support Market Growth with 70 Drugs Set for Approval or Being Evaluated

Subjects
AstraZeneca PLC -- Reports -- Growth, Biopharmaceutics -- Reports, Respiratory agents -- Reports, Pharmaceutical industry -- Industry forecasts, Company growth, General interest, News, opinion and commentary
Abstract

DUBLIN: RESEARCH AND MARKETS has issued the following news release: The 'Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key [...]

Published
2023

38. Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Subjects
Boehringer Ingelheim GmbH -- Reports, Roche Holding AG -- Reports, Business -- Research, Biological products -- Reports, Biotechnology industry -- Reports, Viral antibodies -- Reports, Clinical trials -- Reports, Antibodies -- Reports, Pharmaceutical industry -- Reports, General interest, News, opinion and commentary
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: DelveInsight's 'Bispecific Antibody Competitive Landscape - 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific [...]

Published
2023

39. ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(r) in Relapsed|Refractory DLBCL

Subjects
ADC Therapeutics S.A., Non-Hodgkin's lymphomas, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following press release: ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA(r) (loncastuximab [...]

Published
2023

40. Sobi to present new data at the 2023 EHA congress

Subjects
Hemophilia -- Political aspects, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Swedish Orphan Biovitrum AB has issued the following news release: Sobi(r) will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, [...]

Published
2023

41. ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

Subjects
ADC Therapeutics S.A. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC THERAPEUTICS SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter 2023 and provided an updated corporate strategy. [...]

Published
2023

42. IGM Biosciences, Inc. Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023

Subjects
Oncology, Experimental -- Conferences, meetings and seminars, Societies -- Conferences, meetings and seminars -- Research, T cells -- Conferences, meetings and seminars -- Research, Biotechnology -- Conferences, meetings and seminars -- Research, Biotechnology industry -- Conferences, meetings and seminars -- Research, B cells -- Conferences, meetings and seminars -- Research, Cancer -- Conferences, meetings and seminars -- Research, Associations, institutions, etc. -- Conferences, meetings and seminars -- Research, General interest, News, opinion and commentary
Abstract

MOUNTAIN VIEW: IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced the presentation of six posters at the upcoming American Association for Cancer [...]

Published
2023

44. Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio

Subjects
ADC Therapeutics S.A. -- Forecasts and trends -- Growth, Lymphomas -- Forecasts and trends, Drug approval -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends -- Market size -- Growth, Company growth, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

NEW YORK: Technavio has issued the following news release: The diffuse large B-cell lymphoma (DLBCL) therapeutics market size is forecast to grow by USD 2,061.88 million between 2022 and 2027, [...]

Published
2023

47. FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS

Subjects
ADC Therapeutics S.A., Biological products, Biological markers, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Freenome Holdings, Inc. has issued the following news release: Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual [...]

Published
2022

48. ADC Therapeutics SA (ADCT) drops 4.62% in the last week

Subjects
ADC Therapeutics S.A., Financial markets, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

This Week (November 14, 2022 to November 18, 2022) was unprofitable week for ADC Therapeutics SA (ADCT) at NASDAQ Stock Market, in which it lowered down to $3.92 from the [...]

Published
2022

49. ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Subjects
ADC Therapeutics S.A. -- Officials and employees -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings -- Officials and employees, Company earnings/profit, General interest, News, opinion and commentary
Abstract

LAUSANNE: ADC Therapeutics SA has issued the following news release: ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided business [...]

Published
2022

50. ADC Therapeutics SA (ADCT) drops 6.21% in the last week

Subjects
ADC Therapeutics S.A. -- Officials and employees, Financial markets, Pharmaceutical industry -- Officials and employees, General interest, News, opinion and commentary
Abstract

This Week (October 31, 2022 to November 4, 2022) was unprofitable week for ADC Therapeutics SA (ADCT) at NASDAQ Stock Market, in which it lowered down to $4.23 from the [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results